4D Molecular Therapeutics, Inc. (FDMT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Company Overview - 4D Molecular Therapeutics is a next-generation gene therapy company founded approximately 12 years ago, focusing on developing tissue-specific vectors and capsids through a platform called directed evolution [2] - The company aims to deliver safer doses and target larger market therapeutic areas rather than just rare diseases, which is common in many gene therapies [2] Lead Program - The lead program of the company is 4D-150, which is currently progressing through Phase III trials [3] - This program targets retinal diseases, with lead indications for wet age-related macular degeneration and plans to initiate a Phase III trial for diabetic macular edema in the future [3]